

Ganovo gets enrolled in basic medical Insurance of Tianjin

27 September 2018 | News

The Pilot Program supports hepatitis C patients get timely access to most innovative treatments and aims to eliminate hepatitis C in China by 2030.



Ascletis Pharma Inc. announced that Ganovo (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ("Pilot Program") for outpatients with hepatitis C.

The Pilot Program supports hepatitis C patients get timely access to most innovative treatments and aims to eliminate hepatitis C in China by 2030.

It also creates a new chapter for Ganovo to begin its reimbursement access to the provincial medical reimbursement system. It is anticipated more provinces in China will replicate the Tianjin initiative.

Ganovo is the first DAA developed and commercialized by a domestic company in China. Ganovo inhibits the hepatitis C virus (HCV) NS3/4A protease that is critical to HCV replication.

In phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in genotype 1 non-cirrhotic patients, with 12-week treatment duration.

"The Pilot Program fulfilled the concept of value-based payment. Starting from Tianjin, we anticipate Ganovo® will gain reimbursement access in more provinces and benefit more hepatitis C patients in China", said Jinzi J. Wu, Ph.D., Ascletis' founder, Chairman and CEO.